PI-103

PI-103は一種の多ターゲットPI3K阻害剤で、無細胞試験でp110α/β/δ/γに作用する時のIC50値は2 nM/3 nM/3 nM/15 nMです。PI-103はmTOR/DNA-PKに作用する効果が弱くて、このIC50値が30 nM/23 nMになります。

価格 在庫  
USD 168 あり
USD 185 あり
USD 340 あり
USD 466 あり

PI-103 化学構造
分子量: 348.36

高品質保証

カスタマーフィードバック(4)

MSDS

製品説明

  • Compare PI3K Inhibitors
    PI3K製品生物活性の比較
  • 研究分野
  • PI-103のメカニズム

製品の説明

生物活性

製品説明 PI-103は一種の多ターゲットPI3K阻害剤で、無細胞試験でp110α/β/δ/γに作用する時のIC50値は2 nM/3 nM/3 nM/15 nMです。PI-103はmTOR/DNA-PKに作用する効果が弱くて、このIC50値が30 nM/23 nMになります。
ターゲット p110α p110β p110δ p110γ mTOR DNA-PK
IC50 2 nM 3 nM 3 nM 15 nM 30 nM 23 nM [3]
In vitro試験 PI-103 potently inhibits both the rapamycin-sensitive (mTORC1) and rapamycin-insensitive (mTORC2) complexes of the protein kinase mTOR. [1] PI-103 inhibits constitutive and growth factor-induced PI3K/Akt, as well as mTORC1 activation. [2] In blast cells, PI-103 inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells. PI-103 inhibits p110α >200-fold more potently than p110β. PI-103 also potently blocks production of PI(3,4)P2 and PIP3 in adipocytes and PIP3 in myotubes. [2] PI-103 inhibits phosphorylation of Akt with an IC95 100-fold lower than that for LY294002. Strikingly, PI-103 completely protects animals from insulin-stimulated decline in blood glucose. PI-103 has additive proapoptotic effects with etoposide in blast cells and in immature leukemic cells. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SK-N-BE MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3rWGdZOC16IN88US=> MV2yOE81QC95MjDo NH;EW5FqdmS3Y3XzJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcohq[mm2aX;uJI9vKE6EIHPlcIwh\3Kxd4To NG\ncokzPjJ{NE[4NS=>
SH-SY5Y M{nVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFr4WYExNThizszN MnnUNlQwPDhxN{KgbC=> NWG4TJZ4cW6mdXPld{B1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5pcWKrdHnvckBwdiCQQjDj[YxtKGe{b4f0bC=> MlzINlYzOjR4OEG=
SH-SY5Y  NEW1XHdCeG:ydH;zbZMhSXO|YYm= NVzWdWZ7OSEQvF2= NFfoNo8xNjVvMkSgbC=> M{PUUpNmdnOrdHn6[ZMhdmW3cn;icIF{fG:vYTDj[YxteyC2bzDkc5hwenWkaXPpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> MV6yOlIzPDZ6MR?=
G 35 SC NXrDdVBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fVUVAvODVvMkCg{txO NH\me|gzPC95MjDo Mn3VSG1UVw>? MoLnbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? MUOyOlEzOTJ3MR?=
G 38 SC M{P5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfCU5VWOC5yNT2yNEDPxE1? MUKyOE84OiCq M{TsRmROW09? NGrKPJBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 NIHKWVQzPjF{MUK1NS=>
G 40 SC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYOwMlA2NTJyIN88US=> MlXBNlQwPzJiaB?= MnfMSG1UVw>? MYnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 MUmyOlEzOTJ3MR?=
G 35 DC NFLLPVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{joTlAvODVvMkCg{txO NEK3WFUzPC95MjDo NFLWdpVFVVOR M3vK[4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? NYHicWxROjZzMkGyOVE>
G 38 DC NY\t[HlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HK[lAvODVvMkCg{txO MVWyOE84OiCq M1\JRWROW09? NWfZU|Z1cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= NXf3fXV4OjZzMkGyOVE>
G 40 DC M1zlN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m2SFAvODVvMkCg{txO MUOyOE84OiCq M1LNRWROW09? MWHpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 M1[3blI3OTJzMkWx
RD NXn3[Y9GSXCxcITvd4l{KEG|c3H5 M{[0R|EwOS53L{Kg{txO MXW3NkBp NXX5V4RLcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDHRW5VPjF? NVjoNYt{OjV5NEmzO|g>
TE381.T MmK5RZBweHSxc3nzJGF{e2G7 M4PWcVEwOS53L{Kg{txO M1T5VVczKGh? MVnpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEeDTmS2NS=> MVqyOVc1QTN5OB?=
RMS13 M2juVGFxd3C2b4Ppd{BCe3OjeR?= MmjMNU8yNjVxMjFOwG0> M1PZVlczKGh? M1rOT4lv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiR1HOWFYy MYWyOVc1QTN5OB?=
RH30  M124ZmFxd3C2b4Ppd{BCe3OjeR?= NIL2c3oyNzFwNT:yJO69VQ>? MXO3NkBp MkPnbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCJQV7UOlE> NEHNOoUzPTd2OUO3PC=>
VJ NWmzNWV4SXCxcITvd4l{KEG|c3H5 M{fL[|EwOS53L{Kg{txO M16wV|czKGh? NHzDN5NqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFfBUnQ3OQ>? MYGyOVc1QTN5OB?=
HS578T M1rPXmNmdGxiVnnhZoltcXS7IFHzd4F6 MoDVNE0{KM7:TR?= MXO3NkBp M17MeolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M3u1eFI2PzJzNEG5
BT549 M1m5dmNmdGxiVnnhZoltcXS7IFHzd4F6 Mn\nNE0{KM7:TR?= NXzKZ2lEPzJiaB?= MoSwbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NWe0dHBEOjV5MkG0NVk>
MDA-MB-231 NYfCeXNKS2WubDDWbYFjcWyrdImgRZN{[Xl? NFvwUnMxNTNizszN MYS3NkBp M2P3RolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NWLZbmxqOjV5MkG0NVk>
MDA-MB-468 MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MofaNE0{KM7:TR?= M3vHUlczKGh? NHPRPGtqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NGrzcFgzPTd{MUSxPS=>
MDA-MB-436 NIizfYNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1TV[VAuOyEQvF2= NXrsNmVHPzJiaB?= NIPSTlFqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M4jXZlI2PzJzNEG5
SUM149PT M1W1NGNmdGxiVnnhZoltcXS7IFHzd4F6 MlnXNE0{KM7:TR?= NYfocXhQPzJiaB?= M3y2dYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MUOyOVczOTRzOR?=
MDA-MB-468 NX60eYl1TnWwY4Tpc44hSXO|YYm= MYqwMlAyNTFyIN88US=> MWSyOEBp NEjSWGhld3ewcnXneYxifGW|IITo[UBt\X[nbIOgc4Yh|rJvVILDVFEtKGNvTYnjJIFv\CCleXPsbY4hTSCycn;0[Ylve8Li M172dlI2PzJzNEG5
MDA-MB-231 MXrGeY5kfGmxbjDBd5NigQ>? MkDwNE4xOS1zMDFOwG0> Mn;YNlQhcA>? MUPkc5dvemWpdXzheIV{KHSqZTDs[ZZmdHNib3[g{tIuXHKFUEGsJIMuVXmlIHHu[EBkgWOuaX6gSUBxem:2ZXnud:Kh M{TFbFI2PzJzNEG5
HS578T NGjnV4pHfW6ldHnvckBCe3OjeR?= M{jyflAvODFvMUCg{txO Mly2NlQhcA>? NYizTXR4\G:5boLl[5Vt[XSnczD0bIUhdGW4ZXzzJI9nKM7{LWTyR3AyNCClLV35Z{BidmRiY4njcIlvKEVicILveIVqdnQEoB?= MlHhNlU4OjF2MUm=
SW872 MlKxSpVv[3Srb36gRZN{[Xl? NVXoPZlEOC5yMT2wMlUh|ryP NXTxPWxJOjRiaB?= MX7y[YR2[2W|IFHLWEBxcG:|cHjvdplt[XSrb36gLJBCU1RrIHHu[EA1TUKSMTDwbI9{eGixconsZZRqd25iKIC0SWJROSliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XMEoB?= MX[yOFY6PTZ|Mh?=
SW982 MU\GeY5kfGmxbjDBd5NigQ>? MmXJNE4xOS1yLkWg{txO MYqyOEBp M4XTU5Jm\HWlZYOgRWtVKHCqb4PwbI9zgWyjdHnvckApeEGNVDmgZY5lKDSHQmCxJJBpd3OyaH;yfYxifGmxbjCodFRGSlBzKTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg NXe3PGNuOjR4OUW2N|I>
SW872 MlfERZBweHSxc3nzJGF{e2G7 NX3LW4Z7OC5yMT2wMlUh|ryP MYC0PEBp M3\BUolv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= NVfOdIZVOjR4OUW2N|I>
SW982 MoHzRZBweHSxc3nzJGF{e2G7 NFPLNY8xNjBzLUCuOUDPxE1? NYPNSFVTPDhiaB?= NHLzfGlqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 M{PTfFI1Pjl3NkOy
AGS HG Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzaTWM2OD1yLk[4JOKyKDBwMEOxJO69VQ>? MkL3NlQ2QTd2N{i=
AGS LG MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDmUpJKSzVyPUCuNFUhyrFiMD6wNFEh|ryP NHf4OmEzPDV7N{S3PC=>
HGC27 HG NGHSeopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjnZmJKSzVyPUCuN|ghyrFiMD6wNlIh|ryP MkfJNlQ2QTd2N{i=
HGC27 LG MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;NTWM2OD1yLkCyJOKyKDBwMEC0JO69VQ>? M2PjT|I1PTl5NEe4
MKN45 HG MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XyTWlEPTB;MT6wNUDDuSByLkC1NUDPxE1? NX3FWWxVOjR3OUe0O|g>
MKN45 LG MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm1WlhlUUN3ME2wMlg4KMLzIECuNFMxKM7:TR?= NHrGO|IzPDV7N{S3PC=>
NUGC4 HG MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnrXFBKSzVyPUG0MlAhyrFiMz65NVMh|ryP NWjUbpV5OjR3OUe0O|g>
NUGC4 LG MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX0eohKSzVyPUG0MlAhyrFiNT6zNlEh|ryP MkfVNlQ2QTd2N{i=
A549 MmTaSpVv[3Srb36gRZN{[Xl? M1XwZVAvOjVxMD61M|Eh|ryP NYDoOHJtOjRiaB?= MVXpcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNtcWeqdHz5 Mo[yNlQ{PTF2MkW=
H460 NFPZfJhHfW6ldHnvckBCe3OjeR?= NWX3e205OC5{NT:wMlUwOSEQvF2= MoftNlQhcA>? MkXDbY5pcWKrdIOgRYt1KHCqb4PwbI9zgWyjdHnvckB{dGmpaITsfS=> MYiyOFM2OTR{NR?=
H661 MoDhSpVv[3Srb36gRZN{[Xl? M3:xd|AvOjVxMD61M|Eh|ryP NHXvbHMzPCCq M3;5Z4lvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2mpbnnmbYNidnSueR?= M{W1XlI1OzVzNEK1
SAS MVrGeY5kfGmxbjDBd5NigQ>? NVvRd4ZQOC5{NT:wMlUwOSEQvF2= MoTuNlQhcA>? M1r2ZYlvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2mpbnnmbYNidnSueR?= NWHt[JFOOjR|NUG0NlU>
UT5 NFPVe4NHfW6ldHnvckBCe3OjeR?= NVXTUnZNOC5{NT:wMlUwOSEQvF2= NHS5elUzPCCq M{DpW4lvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2mpbnnmbYNidnSueR?= MlnQNlQ{PTF2MkW=
FaDu Moq4SpVv[3Srb36gRZN{[Xl? MmHnNE4zPS9yLkWvNUDPxE1? M3zSXVI1KGh? M4PWR4lvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2mpbnnmbYNidnSueR?= NXzyRpA6OjR|NUG0NlU>
RD NXvyW|l6SXCxcITvd4l{KEG|c3H5 MX2xM|EvPS9{IN88US=> MVe3NkBp MkC1SG1UVw>? NV\2VI0xcW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDVU|EzPg>? M{DvRVI{Pjh2OUK1
TE671 MY\BdI9xfG:|aYOgRZN{[Xl? MlXYNU8yNjVxMjFOwG0> NEnITVE4OiCq NXXOd2xKTE2VTx?= MnXIbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCXT{GyOi=> MXOyN|Y5PDl{NR?=
RH30  MmDsRZBweHSxc3nzJGF{e2G7 MlO3NU8yNjVxMjFOwG0> MkfjO|IhcA>? NXjSV4h3TE2VTx?= M1;h[4lv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiVV:xNlY> MYGyN|Y5PDl{NR?=
RMS13 NIHFcIZCeG:ydH;zbZMhSXO|YYm= NF\EOJYyNzFwNT:yJO69VQ>? M3Pye|czKGh? NVfENJlTTE2VTx?= NIXEem1qdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIGXPNVI3 M2ThZlI{Pjh2OUK1
SUM149PT NYjTdopsS2WubDDWbYFjcWyrdImgRZN{[Xl? MlfJNE4{KM7:TR?= NUfXV5l5PzJiaB?= NFHOW2NmdmijbnPld{BkgXSxdH;4bYMh\W[oZXP0d{Bw\iCSSUPLM2FMXCCyYYToe4F6KGmwaHnibZRwenN? MnLmNlM3ODFyN{S=
MDA-MB-468 NYTzPIdrS2WubDDWbYFjcWyrdImgRZN{[Xl? NVHHW|E6OC5|IN88US=> MUS3NkBp MX\lcohidmOnczDjfZRwfG:6aXOg[YZn\WO2czDv[kBRUTONL1HLWEBx[XSqd3H5JIlvcGmkaYTvdpM> MV:yN|YxOTB5NB?=
MDA-MB-231 NVjGS5FES2WubDDWbYFjcWyrdImgRZN{[Xl? NH;TZ3QxNjNizszN M3S0NVczKGh? NWHLfWFq\W6qYX7j[ZMh[3m2b4TvfIlkKGWoZnXjeJMhd2ZiUFmzT{9CU1RicHH0bJdigSCrbnjpZol1d3K| NVXGXm9QOjN4MEGwO|Q>
SY5Y M4H6[WZ2dmO2aX;uJGF{e2G7 NXPWSppmOS53L{KuOU82KM7:TR?= NWOzc5pwOjRiaB?= NGLJT5ZqdmS3Y3XzJGcyyqClZXzsMYN6[2ynIHHydoV{fCCjbnSgZZBweHSxc3nz M3noTlI{Ozd6M{Sx
SKNBE(2c) NXj1W|gxTnWwY4Tpc44hSXO|YYm= NUXzbmg{OS53L{KuOU82KM7:TR?= MmjqNlQhcA>? Mo\rbY5lfWOnczDHNeKh[2WubD3jfYNt\SCjcoLld5Qh[W6mIHHwc5B1d3Orcx?= NYTY[IJ1OjN|N{izOFE>
RD MVXBdI9xfG:|aYOgRZN{[Xl? NW\EeY5zOyEEtV2= MknkNVIhcA>? NI\ifJRFVVOR Mnvsd4Vve2m2aYrld{BTTCClZXzsd{B1dyCGT2itbY5lfWOnZDDhdI9xfG:|aYO= M2\ETVI{OzByOEC5
TP5014 MkLYRZBweHSxc3nzJGF{e2G7 MXizJOK2VQ>? NYqzXVR3OTJiaB?= MnrESG1UVw>? MVnz[Y5{cXSrenXzJHJFKGOnbHzzJJRwKESRWD3pcoR2[2WmIHHwc5B1d3Orcx?= NELiWW8zOzNyMEiwPS=>
HT1080 NUfPN2VMSXCxcITvd4l{KEG|c3H5 NYTTfVJrOyEEtV2= NWXuZ4RvOTJiaB?= M{XQWGROW09? NV3pdIsze2Wwc3n0bZpmeyCURDDj[YxteyC2bzDEU3gucW6mdXPl[EBieG:ydH;zbZM> NWDid5VROjN|MEC4NFk>
A549 NGTFc3BHfW6ldHnvckBCe3OjeR?= MXGwMVMvOyEQvF2= MnPXO|IhcA>? NGPZXmJqdmS3Y3XzJINwdXCuZYTlJIRwf26{ZXf1cIF1cW:wIH;mJJBCU1R? NHHpXoUzOzJ3OUW5NS=>
HCC827 M1KwbGZ2dmO2aX;uJGF{e2G7 MWGwMVMvOyEQvF2= MmPKO|IhcA>? NEjCNpdqdmS3Y3XzJINwdXCuZYTlJIRwf26{ZXf1cIF1cW:wIH;mJJBCU1R? Mki1NlMzPTl3OUG=
H3122 M1TMZWZ2dmO2aX;uJGF{e2G7 NEDHNpQxNTNwMzFOwG0> MnrNO|IhcA>? NUjGRlBwcW6mdXPld{Bkd22ybHX0[UBld3ewcnXneYxifGmxbjDv[kBxSUuW NI\sVmczOzJ3OUW5NS=>
TALL-1 Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUKx5qCK|ryP NVnmRmxGPyCm MWnk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> M4[5e|I{ODN6Mkez
HPB-ALL MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfaNgKBkc7:TR?= MXK3JIQ> M4LoV4Rm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? NG\KV5MzOzB|OEK3Ny=>
DND41 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TsclHjiIoQvF2= MmTtO{Bl Mo\3[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NGPLUGczOzB|OEK3Ny=>
SUP-T1 NXjNcZQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\1ZlHjiIoQvF2= MYG3JIQ> M{\UWoRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? NV3HeJRTOjNyM{iyO|M>
PEER M3nlcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTvXoZkOeLCid88US=> M{LZXlch\A>? M3jQU4Rm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? M3fKVVI{ODN6Mkez
ALL-SIL NGDVTZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1T5O|HjiIoQvF2= NYDESoVZPyCm NWXkdoFn\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MV:yN|A{QDJ5Mx?=
KE37 M{jNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzyNgKBkc7:TR?= Mn65O{Bl Mn\F[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NXzxd|NyOjNyM{iyO|M>
Karpas-45 NFqyRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXGyPFlWOeLCid88US=> MnPuO{Bl MXzk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MXWyN|A{QDJ5Mx?=
RPMI-8402 NFX6cVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XoZVHjiIoQvF2= NIrkOFg4KGR? Mn;k[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 Mn\yNlMxOzh{N{O=
Jurkat NIHpeohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVux5qCK|ryP MW[3JIQ> NV74[I9O\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MoPCNlMxOzh{N{O=
MOLT-4 NXXMNm86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLtNgKBkc7:TR?= MUC3JIQ> M3fXeYRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? NGDtW|EzOzB|OEK3Ny=>
PF-382 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nZN|HjiIoQvF2= NYDyd2k4PyCm MmHn[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 MXiyN|A{QDJ5Mx?=
CCRF-CEM Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfQfolnOeLCid88US=> MlzzO{Bl MXXk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> Mnv2NlMxOzh{N{O=
LOUCY NVLLPWgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XzSlHjiIoQvF2= MmjXO{Bl MoPM[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NGLTcHQzOzB|OEK3Ny=>
MOLT-16 NELrelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUex5qCK|ryP NWTFOXpoPyCm M2jZbIRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? NFjrXJIzOzB|OEK3Ny=>
MM1S MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzPfHNbOC1{IN88US=> M3Hz[|I1KGh? MXfJR|UxRTBwNTFOwG0> NF\QRYMzOjh{OUKzOC=>
NCI-H929 NYXBbpRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S4SlAuOiEQvF2= NWTTVm5POjRiaB?= Mmi0TWM2OD1yLkK1JO69VQ>? NIjuc2UzOjh{OUKzOC=>
KMS12-BM  NHP0[HdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWiwMVIh|ryP NV\nVpBIOjRiaB?= MXvJR|Ux97zgMjFOwG0> NWDZdpk4OjJ6MkmyN|Q>
MDA-MB-436 MUnGeY5kfGmxbjDBd5NigQ>? M1LL[VEh|ryP MoX1NlQhcA>? NIjpd3Nz\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvU NXXOb|J{OjJ2OEi1PVA>
SUM149PT NFvxTmpHfW6ldHnvckBCe3OjeR?= MWGxJO69VQ>? NVGxW4MyOjRiaB?= NETXUnlz\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvU NYLVVlk{OjJ2OEi1PVA>
SUM1315MO2 MXrGeY5kfGmxbjDBd5NigQ>? M3P2V|Eh|ryP NV7mR3ZVOjRiaB?= MX\y[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSUuW M4Ox[FIzPDh6NUmw
HCC1937 NGLjSIhHfW6ldHnvckBCe3OjeR?= M2XhOFEh|ryP NVrafo5QOjRiaB?= NX:4dIE3emWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWC=> MojSNlI1QDh3OUC=
HCC827 NGm3T|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWToNYxJOC1|IN88US=> M33ibVczKGh? NWCyN2FwUUN3ME2wMlMh|ryP M4\VdlIyOjJyNEe0
PC-9  MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\T[XlLOC1|IN88US=> NV7pfW04PzJiaB?= M2Lpb2lEPTB;MD64JO69VQ>? MmDCNlEzOjB2N{S=
LN229 NHzsVGZHfW6ldHnvckBCe3OjeR?= M4DKVlEh|ryP M{PtZ|Q5KGh? NVv6VGdEcW6mdXPld{BifXSxcHjh[49{d22nIH\vdo1ifGmxbh?= NEnGUnIzOTB4Mkm5Ny=>
U87 MUTGeY5kfGmxbjDBd5NigQ>? M4LxZ|Eh|ryP MnL3OFghcA>? MnLObY5lfWOnczDheZRweGijZ3;zc41mKG[xcn3heIlwdg>? MYSyNVA3Ojl7Mx?=
U373 M1n3WWZ2dmO2aX;uJGF{e2G7 MUGxJO69VQ>? MVu0PEBp MVXpcoR2[2W|IHH1eI9xcGGpb4PvcYUh\m:{bXH0bY9v NInKU3ozOTB4Mkm5Ny=>
SF767 M1XJTGZ2dmO2aX;uJGF{e2G7 MYGxJO69VQ>? NWrafmVLPDhiaB?= MVzpcoR2[2W|IHH1eI9xcGGpb4PvcYUh\m:{bXH0bY9v MWOyNVA3Ojl7Mx?=
Mel-Juso MUfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkHmNE4xOeLCk{Gw5qCK|ryP NIXTfWE4OiCq MmjibY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NWroWVd[OjFyNEi3PFU>
518A2  M1;2fGNmdGxiVnnhZoltcXS7IFHzd4F6 NFfi[HQxNjBz4pETNVDjiIoQvF2= MoLaO|IhcA>? MYDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 Mn;WNlExPDh5OEW=
Mel-Juso  MmrBSpVv[3Srb36gRZN{[Xl? NGrOdIQxNjByMfMAl|HjiIoQvF2= MWWyOEBp MUDzeZBxemW|c3XzJJBpd3OyaH;yfYxifGmxbjDv[kBxcG:|cHjheIllgWxiaX7vd4l1d2xiMz3rbY5ie2ViZH;3cpN1emWjbTD0ZZJo\XS| MXeyNVA1QDd6NR?=
518A2 NGT3bmtHfW6ldHnvckBCe3OjeR?= M3PCNVAvODBz4pETNgKBkc7:TR?= M1vHRVI1KGh? MmDTd5VxeHKnc4Pld{BxcG:|cHjvdplt[XSrb36gc4YheGixc4DoZZRq\HmuIHnuc5NqfG:uIEOtb4lv[XOnIHTve45{fHKnYX2geIFz\2W2cx?= MXuyNVA1QDd6NR?=
PC3  NXPvXXBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;TfVI1cA>? MYLHTVUxyqB;IEGwNEBvVQ>? M4\4elIxPTVzME[x
U87MG Mmm3SpVv[3Srb36gRZN{[Xl? NUTOdGs1OC5zLUGg{txO MYKyOQKBkWkEoB?= NFe2OmpFVVOR NUTINGFHcW6qaXLpeJMhWEl|Sz3t[YRq[XSnZDDzbYdv[Wyrbne= NF2weIYyQTZ|M{[4Ny=>
U138MG MorCSpVv[3Srb36gRZN{[Xl? MWiwMlEuOSEQvF2= M{fBU|I16oDLaNMg M3PoXWROW09? NX;xNXpycW6qaXLpeJMhWEl|Sz3t[YRq[XSnZDDzbYdv[Wyrbne= NVnabJlsOTl4M{O2PFM>
U118MG NVXFS5JLTnWwY4Tpc44hSXO|YYm= NHiyR44xNjFvMTFOwG0> M37je|I16oDLaNMg M1\uZmROW09? NIL1OYhqdmirYnn0d{BRUTONLX3l[IlifGWmIIPp[45idGmwZx?= M{jj[lE6PjN|Nkiz
U87MG MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMUSg{txO NELoSI0yQTV6NEKyOy=>
IGROV-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHITWM2OD1yLkC2JO69VQ>? MnvxNVk2QDR{Mke=
DETROIT562 M2fxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnSTWM2OD1yLkGzJO69VQ>? MVGxPVU5PDJ{Nx?=
PC3  MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PnN2lEPTB;MD6xNEDPxE1? MUexPVU5PDJ{Nx?=
SKOV-3 M2j4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXzZYd4UUN3ME2wMlEzKM7:TR?= Mk[5NVk2QDR{Mke=
HUVEC M33we2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLhTWM2OD1yLkC4JO69VQ>? NGfXb4gyQTV6NEKyOy=>
UCH-1  Mor1SpVv[3Srb36gRZN{[Xl? Mn\PNE02KM7:TR?= NFTDSVBqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIHLveIghSUuWIHHu[EBuXE:UIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NFnyWHgyQTV{OES0NS=>
UCH-1  NXe5[3M6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NECzOXgxNjBzLUGwJO69VQ>? NVzSUIk4PiCm NGG0[Y1qdmirYnn0d{Bxem:uaX\ldoF1cW:wIHTvd4Uh\GWyZX7k[Y51dHl? NXvYSpo2OTl3Mki0OFE>
UCH-1  NFn1T|VCeG:ydH;zbZMhSXO|YYm= NGLDWpMxNjFvMUCg{txO M2\xNVI1KGh? MljLSG1UVw>? MnrMbY5lfWOnczDhdI9xfG:|aYO= M4HrVlE6PTJ6NESx

... Click to View More Cell Line Experimental Data

In vivo試験 When tumors reach 50-100 mm3, animals are randomized and treated with vehicle or PI-103. PI-103 exhibits significant activity, decreasing average tumor size by 4-fold after 18 days. [2] Mice treated with PI-103 have no obvious signs of toxicity premorbidly (based on body weight, food and water intake, activity, and general exam) or at necropsy. Treated tumors display decreased levels of phosphorylated Akt and S6, consistent with blockade of p110α and mTOR. PI-103 treatment is cytostatic to glioma xenografts. [2]
臨床試験
特集 The first potent, synthetic mTOR inhibitor.

プロトコル (参考用のみ)

キナーゼアッセイ: [3]

Enzyme Assays Phosphatidylinositide 3-kinase inhibitory activity was determined using a scintillation proximity assay in the presence of 1 μmol/L ATP. Inhibition of mTOR protein kinase was determined using a TR-FRET-based LanthaScreen method from Invitrogen. Compounds were assayed at a maximum concentration of 10 μmol/L in the presence of 1 μmol/L ATP, and IC50 values were determined using GraphPad Prism software.

細胞アッセイ: [2]

細胞株 U87MG cells
濃度 0.5 μM
反応時間 24 hours
実験の流れ U87MG cells are treated with PI-103 for 24 hours. Cell death is quantified by colorimetric determination of LDH activity using a cytotoxicity detection kit. Percentage of cell death (mean of three 12-well plates per experimental point) is calculated [(experimental value- low control)/(high control -low control) × 100], where the low-control cells are DMSO treated and high-control cells are Triton treated (1% Triton X-100, 30 min, 37 °

動物実験: [2]

動物モデル 6- to 12-week-old Balbc nu/nu mice bearing U87MG:ΔEGFR cells
製剤 50% DMSO
投薬量 5 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download PI-103 SDF
分子量 348.36
化学式

C19H16N4O3

CAS No. 371935-74-9
保管 3年-20℃
2年-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 24 mg/mL (68.89 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Phenol, 3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]-

文献中の引用 (21)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related PI3K 阻害剤

  • GDC-0032

    GDC-0032は一種有効的で、次世代のβ亜型PI3K阻害剤で、PI3Kα/δ/γに作用する時のIC50値が0.29 nM/0.12 nM/0.97nMそれぞれ分かれます。GDC-0032はPI3Kα/δ/γに作用する選択性はPI3Kβに作用する選択性より10倍以上が高くなります。

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147)は一種の選択性的で、可逆なI型PI3K阻害剤で、無細胞試験でPI3Kα/δ/γに作用する時のIC50値が39 nM/36 nM/23 nMそれぞれに分かれて、PI3Kβに低い作用をしています。臨床1/2期。

  • GNE-317

    GNE-317は一種の有効な大脳浸透性のPI3K阻害剤です。

  • PI-3065

    PI-3065は一種の選択性p110δ阻害剤で、IC50値が15 nMです。PI-3065は選択性について、他のPI3K家族メンバーより70倍以上が高くなります。

  • LY294002

    LY294002は初めの合成で、PI3Kα/δ/βを抑制することが分かった小分子です。無細胞試験で、IC50値は0.5 μM/0.57 μM/0.97 μMそれぞれに分かれます。尚、溶液にの状況はワートマニン(Wortmannin)にの状況よりもっと安定になって、自食胞の形成も遮断できます。

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA)は1種の選択性PI3K阻害剤で、HeLa細胞の中で、Vps34とPI3Kγに作用する時のIC50値は25μMと60μMです。3-Methyladenine (3-MA)はI型PI3Kを永遠に抑制しますが、III型PI3Kを一時に抑制して、自食体の形成も遮断します。

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101)は1種のセレクティブp110δ阻害剤です。無細胞試験で、IC50値は2.5 nMです。CAL-101 (Idelalisib, GS-1101)はp110δに表現する選択性はp110α/β/γに表現する選択性 より40-300倍が高くなって、C2β、hVPS34、DNA-PK とmTORに表現する選択性より400-4000倍が高くなります。

  • Wortmannin

    Wortmanninは一種、初めに命名されたPI3K阻害剂で、無細胞試験でIC50値が3 nMになって、PI3K家族に作用する選択性が弱くて、自食体の形成も抑制して、DNA-PK/ATMも有効に抑制して、無細胞試験で、このIC50値が16 nMと150 nMになります。

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235,Dactolisib)は一種の二重ATP競争性PI3KとmTOR阻害剤で、無細胞試験でp110α/γ/δ/β/mTOR(p70S6K)を抑制する時のIC50値は 4 nM /5 nM /7 nM /75 nM /6 nMそれぞれ分かれます。BEZ235 (NVP-BEZ235,Dactolisib)はT3TopBP1-ER 細胞の中でATRを抑制して、IC50 値が21 nMになって、Akt とPDK1に作用することが弱くなります。臨床2期。

  • BKM120 (NVP-BKM120, Buparlisib)

    BKM120 (NVP-BKM120, Buparlisib)は1種のセレクティブPI3K阻害剤で、無細胞試験でp110α/β/δ/γに作用する時のIC50値は52 nM/166 nM/116 nM/262 nMそれぞれに分かれます。BKM120 (NVP-BKM120, Buparlisib)はVPS34、mTORとDNAPKに作用する効果が良くなくて、PI4Kβにほとんど活性を表しません。臨床2期。

最近チェックしたアイテム

Tags: PI-103を買う | PI-103供給者 | PI-103を購入する | PI-103費用 | PI-103生産者 | オーダーPI-103 | PI-103代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ